Economic burden of drug-induced anaphylaxis: what can we do better?
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions. Although DIA has a relevant societal impact, there are limited and heterogenous available data related to its cost. Direct costs related to the management of acute phase of DIA was estimated by $529.6 to $3125, depending on the number of emergency room visits/hospitalizations, emergency kits and transports in ambulance. Direct costs of investigations of DIA varied from $288 to $2292.95 and the desensitization was estimated by $6796. Main variables for this were: personnel, allergy screening procedures, medical consumables and space cost. The mean indirect cost was based on a mean absenteeism of 3 days per DIA corresponding to $381.2. More than reviewing the published data, we were able to identify variables that, if correctly managed, can reduce the economic burden of DIA, such as adjusting the timing of referral and etiological diagnosis, identification of potential risk and/or co-factors, correct written recommendations to patients. The evidence presented highlights the need of optimization of healthcare patients to patients suffering from DIA.
Identifiants
pubmed: 35852897
doi: 10.1097/ACI.0000000000000836
pii: 00130832-202208000-00006
doi:
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
234-241Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.
The American Academy of Allergy, Asthma and I. Anaphylaxise AAAAI. Available at: https://www.aaaai.org/conditions-and-treatments/allergies/anaphylaxis . Accessed April 11, 2021
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082–1123.
Lee S, Hess EP, Lohse C, et al. Trends, characteristics, and incidence of anaphylaxis in 2001–2010: a population-based study. J Allergy Clin Immunol 2017; 139:182–188.
Regateiro FS, Marques ML, Gomes ER. Drug-induced anaphylaxis: an update on epidemiology and risk factors. Int Arch Allergy Immunol 2020; 181:481–487.
Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract 2021; 9:819.e2–829.e2.
Jares EJ, De Falco A, Sánchez-Borges M, et al. Drug-induced anaphylaxis and drug sales. Ann Allergy, Asthma Immunol 2020; 125:489.e1–490.e1.
Simons FER, Ardusso LRF, Dimov V, et al. World allergy organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013; 162:193–204.
Faria E, Rodrigues-Cernadas J, Gaspar A, et al. Drug-induced anaphylaxis survey in Portuguese Allergy Departments. J Investig Allergol Clin Immunol 2014; 24:40–48.
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States. Arch Intern Med 2001; 161:15.
Wood RA, Camargo CA, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol 2014; 133:461–467.
Corriger J, Beaudouin E, Rothmann R, et al. Epidemiological data on anaphylaxis in French emergency departments. J Investig Allergol Clin Immunol 2019; 29:357–364.
Tuttle KL, Wickner P. Capturing anaphylaxis through medical records. Ann Allergy Asthma Immunol 2020; 124:150–155.
Tanno LK, Chalmers R, Bierrenbach AL, et al. Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11. J Allergy Clin Immunol 2019; 144:627–633.
National Library of Medicine. National Information Center on Health Services Research and Healthcare Technology (NICHSR). Available at: https://www.nlm.nih.gov/nichsr/edu/healthecon/glossary.html#Cost_of_illness . Accessed November 15, 2021.
Organization WA. White Book on Allergy: Update 2013. Published online 2013.
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 349:g7647–g17647.
Blumenthal KG, Li Y, Banerji A, et al. The cost of penicillin allergy evaluation. J Allergy Clin Immunol Pract 2018; 6:1019.e2–1027.e2.
Krasnick J, Patterson R, Harris KE. Idiopathic anaphylaxis: long-term follow-up, cost, and outlook. Allergy 1996; 51:724–731.
Sloane D, Govindarajulu U, Harrow-mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 2016; 4:497–504.
Flabbee J, Petit N, Jay N, et al. The economic costs of severe anaphylaxis in France: an inquiry carried out by the Allergy Vigilance Network. Allergy Eur J Allergy Clin Immunol 2008; 63:360–365.
World Health Organization. WHO Guide to Identifying the Economic Consequences of Disease and Injury. Department of Health Systems Financing Health Systems; 2019. doi:10.4324/9781351172523-6.
Sousa-Pinto B, Cardoso-Fernandes A, Araújo L, et al. Clinical and economic burden of hospitalizations with registration of penicillin allergy. Ann Allergy Asthma Immunol 2018; 120:190.e2–194.e2.
Sousa-Pinto B, Blumenthal KG, Macy E, et al. Penicillin allergy testing is cost-saving: an economic evaluation study. Clin Infect Dis 2021; 72:924–938.
Kong Cardoso B, Silva L, Magalhães AM, et al. Primary care doctors’ attitude towards drug allergy in Portugal. A questionnaire. Eur Ann Allergy Clin Immunol 2021; doi: 10.23822/EurAnnACI.1764-1489.216.
doi: 10.23822/EurAnnACI.1764-1489.216
Blanca M, Torres MJ, García JJ, et al. Natural evolution of skin test sensitivity in patients allergic to β-lactam antibiotics. J Allergy Clin Immunol 1999; 103:918–924.
Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy 2014; 69:420–437.
Su T, Broekhuizen BDL, Verheij TJM, et al. The impact of penicillin allergy labels on antibiotic and healthcare use in primary care: a retrospective cohort study. Clin Transl Allergy 2017; 7:18.
Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. JAMA 2019; 321:188.
Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 2016; 4:497–504.
Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69:1026–1045.
Tanno LK, Bierrenbach AL, Calderon MA, et al. Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy Eur J Allergy Clin Immunol 2017; 72:120–125.
Tanno LK, Touati N, Allichon S, et al. A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis. J Allergy Clin Immunol Pract 2021; 9:676.e1–683.e1.
Tanno LK, Chalmers R, Jacob R, et al. Global implementation of the world health organization's International Classification of Diseases (ICD)-11: the allergic and hypersensitivity conditions model. Allergy Eur J Allergy Clin Immunol 2020; 75:2206–2218.
Chen JR, Tarver SA, Alvarez KS, et al. Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline. Open Forum Infect Dis 2018; 5: doi:10.1093/ofid/ofy106.
doi: 10.1093/ofid/ofy106
King EA, Challa S, Curtin P, Bielory L. Penicillin skin testing in hospitalized patients with β-lactam allergies. Ann Allergy Asthma Immunol 2016; 117:67–71.
Jefferson AA, Khan DA, Shaker MS. The penicillin allergy label: expensive to maintain, inexpensive to remove. J Allergy Clin Immunol Pract 2018; 6:1028–1029.
Thong B, Vervloet D, Jaén MJT. Drug allergies. Published 2021. Available at: https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/drug-allergies .
Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. J Allergy Clin Immunol Pract 2019; 7:103–111.
Lieberman P, Camargo CA, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596–602.